Table 5. Prognostic factors of high-grade serous ovarian carcinoma.

		Progression-free survival		Overall survival
	No.	HR (95%CI)	P-value	HR (95%CI)	P-value
Age			0.38		0.90
< 70	90	1		1
≥ 70	31	0.80 (0.49-1.32)		0.97 (0.55-1.70)
Race			0.74		0.81
Non-White	19	1		1
White	102	0.91 (0.51-1.61)		0.92 (0.48-1.76)
CA125 (IU/L)			0.18		0.66
<35	2	1		1
≥35	60	3.57 (0.48-26.4)		1.56 (0.21-11.5)
LVSI			0.001*		0.01*
No	20	1		1
Yes	101	2.81 (1.45-5.44)		2.84 (1.23-6.59)
Stage			0.006		0.09
I and II	6	1		1
III and IV	115	9.78 (1.34-71.3)		4.71 (0.65-34.0)
Cytoreduction			<0.001*		<0.001*
Suboptimal	71	1		1
Optimal	50	0.39 (0.25-0.61)		0.32 (0.19-0.56)
p53			0.45		0.79
No	34	1		1
Yes	85	0.84 (0.53-1.32)		0.93 (0.54-1.59)
MDR1			0.58		0.89
No	96	1		1
Yes	16	1.18 (0.66-2.10)		0.95 (0.48-1.88)
EGFR			0.18		0.16
No	48	1		1
Yes	63	1.36 (0.87-2.13)		1.47 (0.85-2.53)
HER2			0.89		0.57
No	88	1		1
Yes	32	1.04 (0.63-1.71)		1.19 (0.67-2.11)
ER			0.042		0.22
No	15	1		1
Yes	98	2.03 (1.01-4.06)		1.76 (0.70-4.40)
PR			0.42		0.83
No	102	1		1
Yes	10	0.71 (0.31-1.63)		0.90 (0.36-2.25)
DNA aneuploid			0.19		0.99
No	19	1		1
Yes	99	0.69 (0.40-1.20)		1.01 (0.53-1.93)
S-phase fraction			0.87		0.65
<11%	70	1		1
≥11%	48	0.97 (0.63-1.48)		1.12 (0.67-1.83)

P-values for Log-rank test (univariate).

^*LVSI and optimal cytoreduction remained significant variables in multivariate analysis (Cox proportional hazard regression test with conditional backward method). Abbreviations: No., number of cases; HR, hazard ratio; 95%CI, 95% confidence interval; MDR1, multi-drug resistance 1; EGFR, epidermal growth factor receptor, HER2, human epidermal growth factor receptor 2; ER, estrogen receptor alpha; and PR, progesterone receptor.